Annual report pursuant to Section 13 and 15(d)

Schedule of Accrued Expenses (Details)

v3.22.4
Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Payroll and incentives $ 1,705 $ 1,343
Deferred revenue * [1] 721 33
General and administrative expenses 455 195
Research and development expenses 130 381
Other deferred liabilities ** [2] 88 899
Total $ 3,099 $ 2,851
[1] At December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 is related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”). Both balances are expected to be recognized by March 31, 2023. At December 31, 2021, the balance of $33 was related to the Genentech Agreement. (See Note 9 – Revenue Recognition, Collaboration Agreements, and Other research and Development Agreements).
[2] At December 31, 2022 and December 31, 2021, the balances of $88 and $899, respectively, related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements).